Please login to the form below

Not currently logged in
Email:
Password:

Eliquis

This page shows the latest Eliquis news and features for those working in and with pharma, biotech and healthcare.

Opdivo trial overshadows BMS financial results

Opdivo trial overshadows BMS financial results

Older cardiovascular drug Eliquis  (apixaban) led the charge this quarter with a 24% increase to $2.04bn, while Yervoy also put in a good showing with a 37% hike to $367m.

Latest news

More from news
Approximately 14 fully matching, plus 73 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
huumun formerly PharmiWeb Solutions

huumun, is a digital transformation business. For us, digital transformation means using digital technologies, not just to turn an existing...

Latest intelligence

Report: Customer experience, shaping digital healthcare
In this issue of ‘Perspective’ we speak with industry experts to learn about the world of digital healthcare, and how pharma is beginning to utilise these modern technologies to enhance...
Biomarker
Encouraging signs in biomarker R&D
The cancer immunotherapy firms ramping-up biomarker R&D...
Programmatic methodology and why you should be using it
What is it? How does it work? Why is everyone talking about it? By Richard Webb - Associate Director...

Infographics